DE69735763T2 - Intravaskuläre verabreichung von medikamenten durch elektroporation - Google Patents
Intravaskuläre verabreichung von medikamenten durch elektroporation Download PDFInfo
- Publication number
- DE69735763T2 DE69735763T2 DE69735763T DE69735763T DE69735763T2 DE 69735763 T2 DE69735763 T2 DE 69735763T2 DE 69735763 T DE69735763 T DE 69735763T DE 69735763 T DE69735763 T DE 69735763T DE 69735763 T2 DE69735763 T2 DE 69735763T2
- Authority
- DE
- Germany
- Prior art keywords
- electrode
- catheter
- vessel
- catheter device
- electrodes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000004520 electroporation Methods 0.000 title claims description 38
- 239000003814 drug Substances 0.000 title claims description 23
- 239000000203 mixture Substances 0.000 claims description 66
- 238000001802 infusion Methods 0.000 claims description 22
- 230000005684 electric field Effects 0.000 claims description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 210000001367 artery Anatomy 0.000 description 76
- 229960002897 heparin Drugs 0.000 description 55
- 229920000669 heparin Polymers 0.000 description 55
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 47
- 238000000034 method Methods 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 36
- 229940079593 drug Drugs 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 238000011282 treatment Methods 0.000 description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 11
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 210000003128 head Anatomy 0.000 description 9
- 230000007774 longterm Effects 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 208000037803 restenosis Diseases 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 8
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 8
- 239000004020 conductor Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 229910052709 silver Inorganic materials 0.000 description 8
- 239000004332 silver Substances 0.000 description 8
- 229960000187 tissue plasminogen activator Drugs 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 150000001720 carbohydrates Chemical group 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000003511 endothelial effect Effects 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 4
- 239000004019 antithrombin Substances 0.000 description 4
- 239000003990 capacitor Substances 0.000 description 4
- 210000001715 carotid artery Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000003090 iliac artery Anatomy 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000003973 paint Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 102000004411 Antithrombin III Human genes 0.000 description 3
- 108090000935 Antithrombin III Proteins 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 108010007267 Hirudins Proteins 0.000 description 3
- 102000007625 Hirudins Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000002399 angioplasty Methods 0.000 description 3
- 229960005348 antithrombin iii Drugs 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 229940006607 hirudin Drugs 0.000 description 3
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 108010023197 Streptokinase Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000003489 abdominal muscle Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229950009941 chloralose Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000001621 ilium bone Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000014508 negative regulation of coagulation Effects 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 229960005202 streptokinase Drugs 0.000 description 2
- -1 sulfate polysaccharides Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- GQGRDYWMOPRROR-XUSMOFMBSA-N (z)-7-[(1r,2r,3s,5s)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid Chemical compound O([C@H]1C[C@@H]([C@@H]([C@H]1CC\C=C/CCC(O)=O)N1CCCCC1)O)CC(C=C1)=CC=C1C1=CC=CC=C1 GQGRDYWMOPRROR-XUSMOFMBSA-N 0.000 description 1
- NJPVZSIGDRLLTD-UHFFFAOYSA-N 1-{3-[(4-pyridin-2-ylpiperazin-1-yl)sulfonyl]phenyl}-3-(1,3-thiazol-2-yl)urea Chemical compound C=1C=CC(S(=O)(=O)N2CCN(CC2)C=2N=CC=CC=2)=CC=1NC(=O)NC1=NC=CS1 NJPVZSIGDRLLTD-UHFFFAOYSA-N 0.000 description 1
- XTNWJMVJVSGKLR-UHFFFAOYSA-N 2-[4-[2-(benzenesulfonamido)ethyl]phenoxy]acetic acid Chemical compound C1=CC(OCC(=O)O)=CC=C1CCNS(=O)(=O)C1=CC=CC=C1 XTNWJMVJVSGKLR-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010051113 Arterial restenosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010012088 Fibrinogen Receptors Proteins 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000004032 Heparin Cofactor II Human genes 0.000 description 1
- 108090000481 Heparin Cofactor II Proteins 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 102000016551 L-selectin Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 102000008212 P-Selectin Human genes 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 1
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010056281 Viral vasculitis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- WZSUOQDIYKMPMT-UHFFFAOYSA-N argon krypton Chemical compound [Ar].[Kr] WZSUOQDIYKMPMT-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000003715 calcium chelating agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 239000002565 heparin fraction Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000005468 ion implantation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037333 procollagen synthesis Effects 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229950001172 sulotroban Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960000363 trapidil Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A61N1/303—Constructional details
- A61N1/306—Arrangements where at least part of the apparatus is introduced into the body
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US668725 | 1996-06-24 | ||
| US08/668,725 US5944710A (en) | 1996-06-24 | 1996-06-24 | Electroporation-mediated intravascular delivery |
| PCT/US1997/010975 WO1997049450A1 (en) | 1996-06-24 | 1997-06-23 | Electroporation-mediated intravascular delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69735763D1 DE69735763D1 (de) | 2006-06-01 |
| DE69735763T2 true DE69735763T2 (de) | 2007-05-10 |
Family
ID=24683482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69735763T Expired - Lifetime DE69735763T2 (de) | 1996-06-24 | 1997-06-23 | Intravaskuläre verabreichung von medikamenten durch elektroporation |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US5944710A (enExample) |
| EP (1) | EP0915721B1 (enExample) |
| JP (1) | JP4126095B2 (enExample) |
| CA (1) | CA2258829C (enExample) |
| DE (1) | DE69735763T2 (enExample) |
| WO (1) | WO1997049450A1 (enExample) |
Families Citing this family (288)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7026299B2 (en) * | 1994-07-12 | 2006-04-11 | Human Genome Sciences, Inc. | Connective tissue growth factor-2 |
| EP1217067A2 (en) * | 1994-07-12 | 2002-06-26 | Human Genome Sciences, Inc. | Connective tissue growth factor-2 |
| US6302875B1 (en) | 1996-10-11 | 2001-10-16 | Transvascular, Inc. | Catheters and related devices for forming passageways between blood vessels or other anatomical structures |
| CA2285056C (en) * | 1997-04-03 | 2004-12-14 | Iacob Mathiesen | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| AU8444798A (en) | 1997-06-30 | 1999-01-25 | Centre National De La Recherche Scientifique | Improved method for transferring nucleic acid into the striped muscle and combination therefor |
| IL133708A0 (en) | 1997-06-30 | 2001-04-30 | Rhone Poulence Rorer S A | Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination thereof |
| US6219577B1 (en) | 1998-04-14 | 2001-04-17 | Global Vascular Concepts, Inc. | Iontophoresis, electroporation and combination catheters for local drug delivery to arteries and other body tissues |
| AU3973599A (en) | 1998-05-08 | 1999-11-29 | Genetronics, Inc. | Electrically induced vessel vasodilation |
| US6027488A (en) * | 1998-06-03 | 2000-02-22 | Genetronics, Inc. | Flow-through electroporation system for ex vivo gene therapy |
| US20040229363A1 (en) * | 1998-06-24 | 2004-11-18 | Ed Nolan | High efficiency transfection based on low electric field strength, long pulse length |
| WO2001000856A1 (en) * | 1999-06-25 | 2001-01-04 | Genetronics, Inc. | High efficiency transfection based on low electric field strength, long pulse length |
| US6800484B2 (en) * | 1998-06-24 | 2004-10-05 | Genetronics, Inc. | High efficiency transfection based on low electric field strength, long pulse length |
| EP1100576B1 (en) * | 1998-06-26 | 2007-08-15 | Genetronics, Inc. | Synergism of photodynamic and electropermeation effects on cell vitality as a novel cytotoxic agent |
| US6463334B1 (en) | 1998-11-02 | 2002-10-08 | Cardiac Pacemakers, Inc. | Extendable and retractable lead |
| US6501990B1 (en) | 1999-12-23 | 2002-12-31 | Cardiac Pacemakers, Inc. | Extendable and retractable lead having a snap-fit terminal connector |
| EP1128866A4 (en) * | 1998-11-12 | 2008-11-05 | Ats Med Inc | ELECTRICALLY MEDIATED ANGIOGENESIS |
| US6363938B2 (en) * | 1998-12-22 | 2002-04-02 | Angiotrax, Inc. | Methods and apparatus for perfusing tissue and/or stimulating revascularization and tissue growth |
| WO2000056395A1 (en) * | 1999-03-25 | 2000-09-28 | Genetronics, Inc. | Method and apparatus for reducing electroporation-mediated muscle reaction and pain response |
| US6702811B2 (en) | 1999-04-05 | 2004-03-09 | Medtronic, Inc. | Ablation catheter assembly with radially decreasing helix and method of use |
| US6317615B1 (en) | 1999-04-19 | 2001-11-13 | Cardiac Pacemakers, Inc. | Method and system for reducing arterial restenosis in the presence of an intravascular stent |
| WO2000067825A1 (en) | 1999-05-07 | 2000-11-16 | Microheart, Inc. | Apparatus and method for delivering therapeutic and diagnostic agents |
| US7147633B2 (en) | 1999-06-02 | 2006-12-12 | Boston Scientific Scimed, Inc. | Method and apparatus for treatment of atrial fibrillation |
| DE60026313D1 (de) * | 1999-07-23 | 2006-04-27 | Uutech Ltd | Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes |
| US6326177B1 (en) | 1999-08-04 | 2001-12-04 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Method and apparatus for intracellular electro-manipulation |
| US7632494B2 (en) * | 1999-09-24 | 2009-12-15 | Proteon Therapeutics, Inc. | Methods for enlarging the diameter of a biological conduit in a human subject |
| US7063838B1 (en) * | 1999-09-24 | 2006-06-20 | Proteon Therapeutics Llc | Methods for treating an artery or vein in a human subject |
| US6587718B2 (en) * | 1999-10-08 | 2003-07-01 | Scimed Life Systems, Inc. | Iontophoretic delivery to heart tissue |
| US6329348B1 (en) | 1999-11-08 | 2001-12-11 | Cornell Research Foundation, Inc. | Method of inducing angiogenesis |
| AU2001276868A1 (en) * | 2000-07-11 | 2002-01-21 | Human Genome Sciences, Inc. | Connective tissue growth factor-2 |
| US20060052328A1 (en) * | 2000-07-11 | 2006-03-09 | Human Genome Sciences, Inc. | Connective tissue growth factor-2 |
| US8251986B2 (en) * | 2000-08-17 | 2012-08-28 | Angiodynamics, Inc. | Method of destroying tissue cells by eletroporation |
| WO2002019966A2 (en) * | 2000-09-06 | 2002-03-14 | Johns Hopkins University | Cardiac arrhythmia treatment methods |
| US20090175790A1 (en) * | 2000-09-06 | 2009-07-09 | The Johns Hopkins University | Cardiac arrhythmia treatment methods and biological pacemaker |
| WO2002087419A2 (en) * | 2001-04-27 | 2002-11-07 | Johns Hopkins University | Biological pacemaker |
| DE10103288A1 (de) * | 2001-01-25 | 2002-08-01 | Patrick Schauerte | Gefäßschleuse zur intravaskulären Nervenstimulation und Flüssigkeitsinfusion |
| AU2002254212A1 (en) * | 2001-03-12 | 2002-09-24 | Irm, Llc | Identification of cellular targets for biologically active molecules |
| US20030186390A1 (en) * | 2001-03-22 | 2003-10-02 | De Jong Gary | Methods for delivering nucleic acid molecules into cells and assessment thereof |
| US6936469B2 (en) | 2001-03-22 | 2005-08-30 | Chromos Molecular Systems Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
| US7294511B2 (en) | 2001-03-22 | 2007-11-13 | Chromos Molecular Systems, Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
| US6625486B2 (en) * | 2001-04-11 | 2003-09-23 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for intracellular delivery of an agent |
| US20020169480A1 (en) * | 2001-05-10 | 2002-11-14 | Qingsheng Zhu | Method and device for preventing plaque formation in coronary arteries |
| US7493162B2 (en) * | 2001-06-15 | 2009-02-17 | Cardiac Pacemakers, Inc. | Pulmonary vein stent for treating atrial fibrillation |
| WO2003013615A1 (en) * | 2001-08-07 | 2003-02-20 | Malone Robert W | Electroporative delivery of molecules to organs |
| US6994706B2 (en) | 2001-08-13 | 2006-02-07 | Minnesota Medical Physics, Llc | Apparatus and method for treatment of benign prostatic hyperplasia |
| US20030170898A1 (en) * | 2001-12-04 | 2003-09-11 | Gundersen Martin A. | Method for intracellular modifications within living cells using pulsed electric fields |
| US20040219660A1 (en) * | 2001-12-14 | 2004-11-04 | Dev Sukhendu B. | Electroporation-mediated intravascular delivery |
| AU2003219805B2 (en) * | 2002-02-15 | 2009-06-04 | Eisai Inc. | Electroporation methods for introducing bioactive agents into cells |
| US7236821B2 (en) * | 2002-02-19 | 2007-06-26 | Cardiac Pacemakers, Inc. | Chronically-implanted device for sensing and therapy |
| US7245963B2 (en) * | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US8209006B2 (en) * | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US8131371B2 (en) | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Methods and apparatus for monopolar renal neuromodulation |
| US8774922B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods |
| US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
| US8145316B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
| US8145317B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods for renal neuromodulation |
| US20110207758A1 (en) | 2003-04-08 | 2011-08-25 | Medtronic Vascular, Inc. | Methods for Therapeutic Renal Denervation |
| US7620451B2 (en) | 2005-12-29 | 2009-11-17 | Ardian, Inc. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
| US6978174B2 (en) | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
| US7653438B2 (en) * | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
| US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
| US8347891B2 (en) | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
| US8774913B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
| US7756583B2 (en) | 2002-04-08 | 2010-07-13 | Ardian, Inc. | Methods and apparatus for intravascularly-induced neuromodulation |
| US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
| US7853333B2 (en) | 2002-04-08 | 2010-12-14 | Ardian, Inc. | Methods and apparatus for multi-vessel renal neuromodulation |
| US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
| US20070135875A1 (en) | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
| US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
| US7162303B2 (en) | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
| US9308044B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
| US20140018880A1 (en) | 2002-04-08 | 2014-01-16 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
| US8150520B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods for catheter-based renal denervation |
| US9308043B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
| US20040082859A1 (en) | 2002-07-01 | 2004-04-29 | Alan Schaer | Method and apparatus employing ultrasound energy to treat body sphincters |
| US20040034336A1 (en) * | 2002-08-08 | 2004-02-19 | Neal Scott | Charged liposomes/micelles with encapsulted medical compounds |
| US7400931B2 (en) * | 2002-09-18 | 2008-07-15 | Cardiac Pacemakers, Inc. | Devices and methods to stimulate therapeutic angiogenesis for ischemia and heart failure |
| US8003618B2 (en) * | 2002-10-02 | 2011-08-23 | The John Hopkins University | Focal calcium channel modulation |
| US7072711B2 (en) * | 2002-11-12 | 2006-07-04 | Cardiac Pacemakers, Inc. | Implantable device for delivering cardiac drug therapy |
| US20050015048A1 (en) * | 2003-03-12 | 2005-01-20 | Chiu Jessica G. | Infusion treatment agents, catheters, filter devices, and occlusion devices, and use thereof |
| US7250041B2 (en) * | 2003-03-12 | 2007-07-31 | Abbott Cardiovascular Systems Inc. | Retrograde pressure regulated infusion |
| US7517342B2 (en) * | 2003-04-29 | 2009-04-14 | Boston Scientific Scimed, Inc. | Polymer coated device for electrically medicated drug delivery |
| US7330851B2 (en) * | 2003-08-18 | 2008-02-12 | Eaglehawk, Limited | Data security through dissembly of data elements or connections between elements |
| US20050131513A1 (en) * | 2003-12-16 | 2005-06-16 | Cook Incorporated | Stent catheter with a permanently affixed conductor |
| US7245973B2 (en) | 2003-12-23 | 2007-07-17 | Cardiac Pacemakers, Inc. | His bundle mapping, pacing, and injection lead |
| US7840263B2 (en) * | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
| US20050209548A1 (en) * | 2004-03-19 | 2005-09-22 | Dev Sukhendu B | Electroporation-mediated intravascular delivery |
| US20050226991A1 (en) * | 2004-04-07 | 2005-10-13 | Hossainy Syed F | Methods for modifying balloon of a catheter assembly |
| US7764995B2 (en) | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
| US7729761B2 (en) * | 2004-07-14 | 2010-06-01 | Cardiac Pacemakers, Inc. | Method and apparatus for controlled gene or protein delivery |
| US7567841B2 (en) | 2004-08-20 | 2009-07-28 | Cardiac Pacemakers, Inc. | Method and apparatus for delivering combined electrical and drug therapies |
| US7937143B2 (en) | 2004-11-02 | 2011-05-03 | Ardian, Inc. | Methods and apparatus for inducing controlled renal neuromodulation |
| US8010191B2 (en) | 2004-12-20 | 2011-08-30 | Cardiac Pacemakers, Inc. | Systems, devices and methods for monitoring efficiency of pacing |
| US8326423B2 (en) | 2004-12-20 | 2012-12-04 | Cardiac Pacemakers, Inc. | Devices and methods for steering electrical stimulation in cardiac rhythm management |
| US8290586B2 (en) | 2004-12-20 | 2012-10-16 | Cardiac Pacemakers, Inc. | Methods, devices and systems for single-chamber pacing using a dual-chamber pacing device |
| US8010192B2 (en) | 2004-12-20 | 2011-08-30 | Cardiac Pacemakers, Inc. | Endocardial pacing relating to conduction abnormalities |
| US8005544B2 (en) | 2004-12-20 | 2011-08-23 | Cardiac Pacemakers, Inc. | Endocardial pacing devices and methods useful for resynchronization and defibrillation |
| US8423139B2 (en) | 2004-12-20 | 2013-04-16 | Cardiac Pacemakers, Inc. | Methods, devices and systems for cardiac rhythm management using an electrode arrangement |
| AR047851A1 (es) | 2004-12-20 | 2006-03-01 | Giniger Alberto German | Un nuevo marcapasos que restablece o preserva la conduccion electrica fisiologica del corazon y un metodo de aplicacion |
| US7850645B2 (en) * | 2005-02-11 | 2010-12-14 | Boston Scientific Scimed, Inc. | Internal medical devices for delivery of therapeutic agent in conjunction with a source of electrical power |
| WO2006123248A2 (en) * | 2005-04-18 | 2006-11-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject |
| US20060259088A1 (en) * | 2005-05-13 | 2006-11-16 | Pastore Joseph M | Method and apparatus for delivering pacing pulses using a coronary stent |
| US20060293730A1 (en) * | 2005-06-24 | 2006-12-28 | Boris Rubinsky | Methods and systems for treating restenosis sites using electroporation |
| US7608275B2 (en) * | 2005-07-22 | 2009-10-27 | The Foundry, Llc | Systems and methods for delivery of a therapeutic agent |
| US20070021803A1 (en) | 2005-07-22 | 2007-01-25 | The Foundry Inc. | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
| EP1942946A4 (en) * | 2005-10-14 | 2009-11-25 | Univ Johns Hopkins | BIOLOGICALLY AVAILABLE CELLS |
| US7616990B2 (en) | 2005-10-24 | 2009-11-10 | Cardiac Pacemakers, Inc. | Implantable and rechargeable neural stimulator |
| US20070149901A1 (en) * | 2005-12-08 | 2007-06-28 | Em-Probe, Inc. | Methods and apparatus for pulsed electromagnetic therapy |
| EP2218479A3 (en) * | 2006-06-28 | 2013-06-05 | Medtronic Ardian Luxembourg S.à.r.l. | Methods and systems for thermally-induced renal neuromodulation |
| US7674249B2 (en) * | 2006-10-16 | 2010-03-09 | The Regents Of The University Of California | Gels with predetermined conductivity used in electroporation of tissue |
| US8738125B1 (en) | 2007-03-30 | 2014-05-27 | University Of South Florida | Devices and methods for delivering molecules to the heart with electric fields |
| US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
| US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
| US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
| US8992517B2 (en) | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
| US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
| US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
| US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
| US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
| US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
| US9598691B2 (en) | 2008-04-29 | 2017-03-21 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
| US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
| US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
| US8849395B2 (en) | 2008-05-30 | 2014-09-30 | Boston Scientific Scimed, Inc. | Guide catheter having vasomodulating electrodes |
| US20100125238A1 (en) * | 2008-11-14 | 2010-05-20 | Therawire, Inc. | Iontophoretic Therapeutic Agent Delivery System |
| EP2384222A2 (en) | 2008-12-19 | 2011-11-09 | Cardiac Pacemakers, Inc. | Devices, methods, and systems including cardiac pacing |
| US8808345B2 (en) | 2008-12-31 | 2014-08-19 | Medtronic Ardian Luxembourg S.A.R.L. | Handle assemblies for intravascular treatment devices and associated systems and methods |
| US8652129B2 (en) | 2008-12-31 | 2014-02-18 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation |
| US8974445B2 (en) | 2009-01-09 | 2015-03-10 | Recor Medical, Inc. | Methods and apparatus for treatment of cardiac valve insufficiency |
| US8632534B2 (en) | 2009-04-03 | 2014-01-21 | Angiodynamics, Inc. | Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD) |
| US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
| US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
| WO2010138919A2 (en) | 2009-05-28 | 2010-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
| BRPI1011317B8 (pt) * | 2009-06-09 | 2021-12-21 | Neuronano Ab | Microeletrodo médico para inserção em tecido mole, feixe de microeletrodo médico e arranjo dos mesmos |
| US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
| US20110112400A1 (en) * | 2009-11-06 | 2011-05-12 | Ardian, Inc. | High intensity focused ultrasound catheter apparatuses, systems, and methods for renal neuromodulation |
| EP2525715A4 (en) * | 2010-01-19 | 2014-06-04 | Medtronic Ardian Luxembourg S R L | METHODS AND APPARATUS FOR RENAL NEUROMODULATION BY STEREOTACTIC RADIOTHERAPY |
| US20110208175A1 (en) * | 2010-02-24 | 2011-08-25 | Medtronic Vascular, Inc. | Methods for Treating Sleep Apnea Via Renal Denervation |
| US8556891B2 (en) | 2010-03-03 | 2013-10-15 | Medtronic Ablation Frontiers Llc | Variable-output radiofrequency ablation power supply |
| US8870863B2 (en) | 2010-04-26 | 2014-10-28 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses, systems, and methods for renal neuromodulation |
| US8565880B2 (en) | 2010-04-27 | 2013-10-22 | Cardiac Pacemakers, Inc. | His-bundle capture verification and monitoring |
| CN103547229B (zh) | 2010-08-05 | 2017-09-26 | 美敦力Af卢森堡有限责任公司 | 用于肾神经调制的低温消融装置、系统及方法 |
| EP2627274B1 (en) | 2010-10-13 | 2022-12-14 | AngioDynamics, Inc. | System for electrically ablating tissue of a patient |
| US9084610B2 (en) | 2010-10-21 | 2015-07-21 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses, systems, and methods for renal neuromodulation |
| WO2012061150A1 (en) | 2010-10-25 | 2012-05-10 | Medtronic Ardian Luxembourg S.a.r.I. | Microwave catheter apparatuses, systems, and methods for renal neuromodulation |
| JP2013544133A (ja) | 2010-10-25 | 2013-12-12 | メドトロニック アーディアン ルクセンブルク ソシエテ ア レスポンサビリテ リミテ | 腎ニューロモジュレーションのためのマルチ電極アレイを有するカテーテル装置ならびに関連のシステムおよび方法 |
| CN103313671B (zh) | 2010-10-25 | 2017-06-06 | 美敦力Af卢森堡有限责任公司 | 用于神经调节治疗的估算及反馈的装置、系统及方法 |
| US9060754B2 (en) | 2010-10-26 | 2015-06-23 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
| US20120136344A1 (en) | 2010-10-26 | 2012-05-31 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
| WO2012068268A2 (en) | 2010-11-17 | 2012-05-24 | Medtronic Ardian Luxembourg S.A.R.L. | Therapeutic renal neuromodulation for treating dyspnea and associated systems and methods |
| WO2012088149A2 (en) | 2010-12-20 | 2012-06-28 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
| WO2012125273A2 (en) | 2011-03-14 | 2012-09-20 | Cardiac Pacemakers, Inc. | His capture verification using electro-mechanical delay |
| JP5759615B2 (ja) | 2011-04-08 | 2015-08-05 | コヴィディエン リミテッド パートナーシップ | 腎交感神経の除神経およびイオン導入薬物送達のためのイオン導入カテーテルシステムならびに方法 |
| EP2701623B1 (en) | 2011-04-25 | 2016-08-17 | Medtronic Ardian Luxembourg S.à.r.l. | Apparatus related to constrained deployment of cryogenic balloons for limited cryogenic ablation of vessel walls |
| US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
| EP2775899B1 (en) | 2011-11-07 | 2017-08-23 | Medtronic Ardian Luxembourg S.à.r.l. | Endovascular nerve monitoring devices and associated systems |
| US9192766B2 (en) | 2011-12-02 | 2015-11-24 | Medtronic Ardian Luxembourg S.A.R.L. | Renal neuromodulation methods and devices for treatment of polycystic kidney disease |
| US9414881B2 (en) | 2012-02-08 | 2016-08-16 | Angiodynamics, Inc. | System and method for increasing a target zone for electrical ablation |
| WO2013134469A1 (en) | 2012-03-07 | 2013-09-12 | Medtronic Ardian Luxembourg Sarl | Selective modulation of renal nerves |
| AU2013230893B2 (en) | 2012-03-08 | 2015-12-03 | Medtronic Af Luxembourg S.A.R.L. | Neuromodulation and associated systems and methods for the management of pain |
| WO2013134492A1 (en) | 2012-03-08 | 2013-09-12 | Medtronic Ardian Luxembourg Sarl | Neuromodulation and associated systems and methods for the treatment of sexual dysfunction |
| JP6195856B2 (ja) | 2012-03-08 | 2017-09-13 | メドトロニック アーディアン ルクセンブルク ソシエテ ア レスポンサビリテ リミテ | 神経調節装置に関するバイオマーカーのサンプリングならびに関連システムおよび方法 |
| WO2013134541A2 (en) | 2012-03-08 | 2013-09-12 | Medtronic Ardian Luxembourg Sarl | Gastrointestinal neuromodulation and associated systems and methods |
| AU2013230781B2 (en) | 2012-03-08 | 2015-12-03 | Medtronic Af Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
| US9883909B2 (en) | 2012-03-08 | 2018-02-06 | Medtronic Ardian Luxembourg S.A.R.L. | Renal neuromodulation methods and systems for treatment of hyperaldosteronism |
| US10258791B2 (en) | 2012-04-27 | 2019-04-16 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter assemblies for neuromodulation proximate a bifurcation of a renal artery and associated systems and methods |
| US9848950B2 (en) | 2012-04-27 | 2017-12-26 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and devices for localized disease treatment by ablation |
| WO2013162721A1 (en) | 2012-04-27 | 2013-10-31 | Medtronic Ardian Luxembourg Sarl | Methods and devices for localized inhibition of inflammation by ablation |
| US20150088113A1 (en) | 2012-04-27 | 2015-03-26 | Medtronic Ardian Luxembourg S.A.R.L. | Cryotherapeutic devices for renal neuromodulation and associated systems and methods |
| US9241752B2 (en) | 2012-04-27 | 2016-01-26 | Medtronic Ardian Luxembourg S.A.R.L. | Shafts with pressure relief in cryotherapeutic catheters and associated devices, systems, and methods |
| US8888773B2 (en) | 2012-05-11 | 2014-11-18 | Medtronic Ardian Luxembourg S.A.R.L. | Multi-electrode catheter assemblies for renal neuromodulation and associated systems and methods |
| US8951296B2 (en) | 2012-06-29 | 2015-02-10 | Medtronic Ardian Luxembourg S.A.R.L. | Devices and methods for photodynamically modulating neural function in a human |
| AU2013293270B2 (en) | 2012-07-25 | 2018-08-16 | Massachusetts Institute Of Technology | Inducible DNA binding proteins and genome perturbation tools and applications thereof |
| US8612022B1 (en) | 2012-09-13 | 2013-12-17 | Invatec S.P.A. | Neuromodulation catheters and associated systems and methods |
| US20140110296A1 (en) | 2012-10-19 | 2014-04-24 | Medtronic Ardian Luxembourg S.A.R.L. | Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods |
| US9044575B2 (en) | 2012-10-22 | 2015-06-02 | Medtronic Adrian Luxembourg S.a.r.l. | Catheters with enhanced flexibility and associated devices, systems, and methods |
| EP3578222B1 (en) | 2012-10-22 | 2024-06-19 | Medtronic Ardian Luxembourg S.à.r.l. | Catheters with enhanced flexibility |
| US9095321B2 (en) | 2012-11-21 | 2015-08-04 | Medtronic Ardian Luxembourg S.A.R.L. | Cryotherapeutic devices having integral multi-helical balloons and methods of making the same |
| US9017317B2 (en) | 2012-12-06 | 2015-04-28 | Medtronic Ardian Luxembourg S.A.R.L. | Refrigerant supply system for cryotherapy including refrigerant recompression and associated devices, systems, and methods |
| US9066726B2 (en) | 2013-03-15 | 2015-06-30 | Medtronic Ardian Luxembourg S.A.R.L. | Multi-electrode apposition judgment using pressure elements |
| US9179974B2 (en) | 2013-03-15 | 2015-11-10 | Medtronic Ardian Luxembourg S.A.R.L. | Helical push wire electrode |
| EP3932470B1 (en) | 2013-03-15 | 2023-07-12 | Medtronic Ardian Luxembourg S.à.r.l. | Controlled neuromodulation systems |
| US10548663B2 (en) | 2013-05-18 | 2020-02-04 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation catheters with shafts for enhanced flexibility and control and associated devices, systems, and methods |
| US9339332B2 (en) | 2013-08-30 | 2016-05-17 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation catheters with nerve monitoring features for transmitting digital neural signals and associated systems and methods |
| US9326816B2 (en) | 2013-08-30 | 2016-05-03 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation systems having nerve monitoring assemblies and associated devices, systems, and methods |
| US20150073515A1 (en) | 2013-09-09 | 2015-03-12 | Medtronic Ardian Luxembourg S.a.r.I. | Neuromodulation Catheter Devices and Systems Having Energy Delivering Thermocouple Assemblies and Associated Methods |
| US9138578B2 (en) | 2013-09-10 | 2015-09-22 | Medtronic Ardian Luxembourg S.A.R.L. | Endovascular catheters with tuned control members and associated systems and methods |
| US10433902B2 (en) | 2013-10-23 | 2019-10-08 | Medtronic Ardian Luxembourg S.A.R.L. | Current control methods and systems |
| EP3099377B1 (en) | 2014-01-27 | 2022-03-02 | Medtronic Ireland Manufacturing Unlimited Company | Neuromodulation catheters having jacketed neuromodulation elements and related devices |
| US10492842B2 (en) | 2014-03-07 | 2019-12-03 | Medtronic Ardian Luxembourg S.A.R.L. | Monitoring and controlling internally administered cryotherapy |
| US10463424B2 (en) | 2014-03-11 | 2019-11-05 | Medtronic Ardian Luxembourg S.A.R.L. | Catheters with independent radial-expansion members and associated devices, systems, and methods |
| US9579149B2 (en) | 2014-03-13 | 2017-02-28 | Medtronic Ardian Luxembourg S.A.R.L. | Low profile catheter assemblies and associated systems and methods |
| US9980766B1 (en) | 2014-03-28 | 2018-05-29 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and systems for renal neuromodulation |
| US10194979B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
| US10194980B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
| US10736690B2 (en) | 2014-04-24 | 2020-08-11 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation catheters and associated systems and methods |
| US10610292B2 (en) | 2014-04-25 | 2020-04-07 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, systems, and methods for monitoring and/or controlling deployment of a neuromodulation element within a body lumen and related technology |
| US10918840B2 (en) | 2014-05-06 | 2021-02-16 | Hydra Vascular Llc | Drug device electroporation system |
| US10709490B2 (en) | 2014-05-07 | 2020-07-14 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter assemblies comprising a direct heating element for renal neuromodulation and associated systems and methods |
| AU2015259303B2 (en) | 2014-05-12 | 2021-10-28 | Arena, Christopher B. | Selective modulation of intracellular effects of cells using pulsed electric fields |
| US12114911B2 (en) | 2014-08-28 | 2024-10-15 | Angiodynamics, Inc. | System and method for ablating a tissue site by electroporation with real-time pulse monitoring |
| US11154712B2 (en) | 2014-08-28 | 2021-10-26 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for assessing efficacy of renal neuromodulation and associated systems and devices |
| EP4389044A3 (en) | 2014-10-01 | 2024-09-11 | Medtronic Ardian Luxembourg S.à.r.l. | Systems and methods for evaluating neuromodulation therapy via hemodynamic responses |
| US11013554B2 (en) | 2014-11-14 | 2021-05-25 | Medtronic Ardian Lexembourg S.A.R.L. | Catheter apparatuses for modulation of nerves in communication with pulmonary system and associated systems and methods |
| WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
| US10694972B2 (en) | 2014-12-15 | 2020-06-30 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
| WO2016100720A1 (en) | 2014-12-17 | 2016-06-23 | Medtronic Ardian Luxembourg S.A.R.L. | Systems and methods for assessing sympathetic nervous system tone for renal neuromodulation therapy |
| TWI906646B (zh) | 2015-06-18 | 2025-12-01 | 美商博得學院股份有限公司 | 降低脫靶效應的ｃｒｉｓｐｒ酶突變 |
| AU2016335755B2 (en) | 2015-10-07 | 2021-07-01 | Mayo Foundation For Medical Education And Research | Electroporation for obesity or diabetes treatment |
| US12110490B2 (en) | 2015-12-18 | 2024-10-08 | The Broad Institute, Inc. | CRISPR enzymes and systems |
| AU2017257274B2 (en) | 2016-04-19 | 2023-07-13 | Massachusetts Institute Of Technology | Novel CRISPR enzymes and systems |
| EP3445853A1 (en) | 2016-04-19 | 2019-02-27 | The Broad Institute, Inc. | Cpf1 complexes with reduced indel activity |
| KR20260004568A (ko) | 2016-04-19 | 2026-01-08 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규한 crispr 효소 및 시스템 |
| US10736692B2 (en) | 2016-04-28 | 2020-08-11 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation and associated systems and methods for the treatment of cancer |
| US12595478B2 (en) | 2016-06-29 | 2026-04-07 | The Broad Institute, Inc. | Crispr-Cas systems having destabilization domain |
| US10231784B2 (en) | 2016-10-28 | 2019-03-19 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and systems for optimizing perivascular neuromodulation therapy using computational fluid dynamics |
| US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
| US10646713B2 (en) | 2017-02-22 | 2020-05-12 | Medtronic Ardian Luxembourg S.A.R.L. | Systems, devices, and associated methods for treating patients via renal neuromodulation to reduce a risk of developing cognitive impairment |
| WO2018175924A1 (en) | 2017-03-24 | 2018-09-27 | The Broad Institute, Inc. | Methods and compositions for regulating innate lymphoid cell inflammatory responses |
| US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
| EP3610266A4 (en) | 2017-04-12 | 2021-04-21 | Massachusetts Eye and Ear Infirmary | TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF |
| US12590288B2 (en) | 2017-04-12 | 2026-03-31 | The Broad Institute, Inc. | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response |
| EP3622092A4 (en) | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
| WO2018213726A1 (en) | 2017-05-18 | 2018-11-22 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| WO2018232195A1 (en) | 2017-06-14 | 2018-12-20 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| KR102761791B1 (ko) | 2017-06-26 | 2025-02-05 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 crispr/cas-아데닌 데아미나아제 기반 조성물, 시스템 및 방법 |
| AU2018204843B2 (en) | 2017-07-05 | 2023-07-27 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for treating anxiety disorders in patients via renal neuromodulation |
| US11160982B2 (en) | 2017-07-05 | 2021-11-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for treating post-traumatic stress disorder in patients via renal neuromodulation |
| US10945788B2 (en) | 2017-07-05 | 2021-03-16 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for treating depression in patients via renal neuromodulation |
| US12049643B2 (en) | 2017-07-14 | 2024-07-30 | The Broad Institute, Inc. | Methods and compositions for modulating cytotoxic lymphocyte activity |
| US12105089B2 (en) | 2017-07-17 | 2024-10-01 | The Broad Institute, Inc. | Cell atlas of the healthy and ulcerative colitis human colon |
| JP2020536580A (ja) | 2017-09-19 | 2020-12-17 | ザ ステート オブ イスラエル， ミニストリー オブ アグリカルチャー アンド ルーラル ディヴェロプメント， アグリカルチュラル リサーチ オーガニゼーション （エーアールオー） （ボルカニ センター） | ゲノム編集された鳥 |
| AU2018338318B2 (en) | 2017-09-21 | 2022-12-22 | Massachusetts Institute Of Technology | Systems, methods, and compositions for targeted nucleic acid editing |
| WO2019071054A1 (en) | 2017-10-04 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS |
| WO2019135816A2 (en) | 2017-10-23 | 2019-07-11 | The Broad Institute, Inc. | Novel nucleic acid modifiers |
| WO2019094955A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas |
| US12221720B2 (en) | 2017-11-13 | 2025-02-11 | The Broad Institute, Inc. | Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells |
| EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH |
| CN111511302B (zh) | 2017-11-17 | 2024-09-17 | 美敦力Af卢森堡有限责任公司 | 用于具有增强的神经靶向的神经调节的系统、设备以及相关联的方法 |
| US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
| WO2019113506A1 (en) | 2017-12-07 | 2019-06-13 | The Broad Institute, Inc. | Methods and compositions for multiplexing single cell and single nuclei sequencing |
| WO2019126709A1 (en) | 2017-12-22 | 2019-06-27 | The Broad Institute, Inc. | Cas12b systems, methods, and compositions for targeted dna base editing |
| US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
| US12458435B2 (en) | 2018-01-24 | 2025-11-04 | Medtronic Ireland Manufacturing Unlimited Company | Multielectrode catheter |
| US11116561B2 (en) | 2018-01-24 | 2021-09-14 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, agents, and associated methods for selective modulation of renal nerves |
| US12082917B2 (en) | 2018-01-24 | 2024-09-10 | Medtronic Ireland Manufacturing Unlimited Company | Systems, devices, and methods for assessing efficacy of renal neuromodulation therapy |
| US11478298B2 (en) | 2018-01-24 | 2022-10-25 | Medtronic Ardian Luxembourg S.A.R.L. | Controlled irrigation for neuromodulation systems and associated methods |
| US11253189B2 (en) | 2018-01-24 | 2022-02-22 | Medtronic Ardian Luxembourg S.A.R.L. | Systems, devices, and methods for evaluating neuromodulation therapy via detection of magnetic fields |
| US10959669B2 (en) | 2018-01-24 | 2021-03-30 | Medtronic Ardian Luxembourg S.A.R.L. | Systems and methods for assessing the efficacy of neuromodulation therapy |
| US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
| US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
| US12390262B2 (en) | 2018-03-13 | 2025-08-19 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| WO2019210268A2 (en) | 2018-04-27 | 2019-10-31 | The Broad Institute, Inc. | Sequencing-based proteomics |
| WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| JP2021532815A (ja) | 2018-08-07 | 2021-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 新規Ｃａｓ１２ｂ酵素およびシステム |
| WO2020041384A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity |
| US20210324357A1 (en) | 2018-08-20 | 2021-10-21 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
| US12421507B2 (en) | 2018-08-20 | 2025-09-23 | The Broad Institute, Inc. | Methods and compositions for optochemical control of CRISPR-CAS9 |
| US11633120B2 (en) | 2018-09-04 | 2023-04-25 | Medtronic Ardian Luxembourg S.A.R.L. | Systems and methods for assessing efficacy of renal neuromodulation therapy |
| WO2020051507A1 (en) | 2018-09-06 | 2020-03-12 | The Broad Institute, Inc. | Nucleic acid assemblies for use in targeted delivery |
| AU2019343045A1 (en) | 2018-09-18 | 2021-05-13 | Vnv Newco Inc. | ARC-based capsids and uses thereof |
| US20220401460A1 (en) | 2018-10-10 | 2022-12-22 | Dana-Farber Cancer Institute, Inc. | Modulating resistance to bcl-2 inhibitors |
| US20220411783A1 (en) | 2018-10-12 | 2022-12-29 | The Broad Institute, Inc. | Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues |
| US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
| US12165743B2 (en) | 2018-11-09 | 2024-12-10 | The Broad Institute, Inc. | Compressed sensing for screening and tissue imaging |
| US12402610B2 (en) | 2018-11-09 | 2025-09-02 | The Broad Institute, Inc. | Methods and compositions for modulating innate lymphoid cell pathogenic effectors |
| MX2021005701A (es) | 2018-11-14 | 2021-09-23 | Broad Inst Inc | Sistema crispr a base de sistemas y métodos de diagnóstico de gotas. |
| US20250043366A1 (en) | 2018-12-13 | 2025-02-06 | The Broad Institute, Inc. | Tiled assays using crispr-cas based detection |
| CN113544266A (zh) | 2018-12-17 | 2021-10-22 | 博德研究所 | Crispr相关转座酶系统和其使用方法 |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| KR20210137499A (ko) | 2019-03-05 | 2021-11-17 | 더 스테이트 오브 이스라엘, 미니스트리 오브 애그리컬처 & 루럴 디벨로프먼트, 애그리컬처럴 리서치 오거니제이션, (에이.알.오.), 볼카니 센터 | 게놈-편집 조류 |
| US12534714B2 (en) | 2019-03-18 | 2026-01-27 | The Broad Institute, Inc. | Type VII CRISPR proteins and systems |
| US20220195514A1 (en) | 2019-03-29 | 2022-06-23 | The Broad Institute, Inc. | Construct for continuous monitoring of live cells |
| WO2020206036A1 (en) | 2019-04-01 | 2020-10-08 | The Broad Institute, Inc. | Novel nucleic acid modifier |
| WO2020236972A2 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| WO2020243661A1 (en) | 2019-05-31 | 2020-12-03 | The Broad Institute, Inc. | Methods for treating metabolic disorders by targeting adcy5 |
| US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
| US12214189B2 (en) | 2019-07-24 | 2025-02-04 | Virginia Tech Intellectual Properties, Inc. | Fourier analysis spectroscopy for monitoring tissue impedance changes and treatment outcome during electroporation-based-therapies |
| WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| CN114786605A (zh) | 2019-10-21 | 2022-07-22 | 英杜基奈克斯公司 | 用于十二指肠脉冲电场治疗的装置、系统和方法 |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| US12485279B2 (en) | 2020-11-25 | 2025-12-02 | Virginia Tech Intellectual Properties, Inc. | Methods for modulating temporal infrastructure of pulsed electric fields |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1481480A (en) * | 1974-02-02 | 1977-07-27 | Kernforschungsanlage Juelich | Process and apparatus for increasing the permeability of the membrane of cells of organisms |
| US4747819A (en) * | 1984-10-29 | 1988-05-31 | Medtronic, Inc. | Iontophoretic drug delivery |
| US4663292A (en) * | 1984-12-21 | 1987-05-05 | Wong Daniel T | High-voltage biological macromolecule transfer and cell fusion system |
| DE68925030T2 (de) * | 1988-01-21 | 1996-07-25 | Massachusetts Inst Technology | Molekültransport durch gewebe mit der verwendung von elektroporation. |
| US5088977A (en) * | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5236413B1 (en) * | 1990-05-07 | 1996-06-18 | Andrew J Feiring | Method and apparatus for inducing the permeation of medication into internal tissue |
| US5498238A (en) * | 1990-06-15 | 1996-03-12 | Cortrak Medical, Inc. | Simultaneous angioplasty and phoretic drug delivery |
| CA2074304C (en) * | 1991-08-02 | 1996-11-26 | Cyril J. Schweich, Jr. | Drug delivery catheter |
| US5507724A (en) * | 1992-07-01 | 1996-04-16 | Genetronics, Inc. | Electroporation and iontophoresis apparatus and method for insertion of drugs and genes into cells |
| US5304120A (en) * | 1992-07-01 | 1994-04-19 | Btx Inc. | Electroporation method and apparatus for insertion of drugs and genes into endothelial cells |
| US5634899A (en) * | 1993-08-20 | 1997-06-03 | Cortrak Medical, Inc. | Simultaneous cardiac pacing and local drug delivery method |
-
1996
- 1996-06-24 US US08/668,725 patent/US5944710A/en not_active Expired - Fee Related
-
1997
- 1997-06-23 JP JP50348098A patent/JP4126095B2/ja not_active Expired - Fee Related
- 1997-06-23 EP EP97932266A patent/EP0915721B1/en not_active Expired - Lifetime
- 1997-06-23 WO PCT/US1997/010975 patent/WO1997049450A1/en not_active Ceased
- 1997-06-23 DE DE69735763T patent/DE69735763T2/de not_active Expired - Lifetime
- 1997-06-23 CA CA002258829A patent/CA2258829C/en not_active Expired - Fee Related
-
2001
- 2001-12-14 US US10/020,531 patent/US20020045853A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20020045853A1 (en) | 2002-04-18 |
| JP4126095B2 (ja) | 2008-07-30 |
| WO1997049450A1 (en) | 1997-12-31 |
| CA2258829C (en) | 2007-12-18 |
| EP0915721B1 (en) | 2006-04-26 |
| EP0915721A1 (en) | 1999-05-19 |
| EP0915721A4 (en) | 2004-08-18 |
| DE69735763D1 (de) | 2006-06-01 |
| JP2000515400A (ja) | 2000-11-21 |
| CA2258829A1 (en) | 1997-12-31 |
| US5944710A (en) | 1999-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69735763T2 (de) | Intravaskuläre verabreichung von medikamenten durch elektroporation | |
| US20050209548A1 (en) | Electroporation-mediated intravascular delivery | |
| DE60100740T2 (de) | Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten | |
| US20020040204A1 (en) | Electroporation-enhanced inhibition of vascular neointimal hyperplasia | |
| US6865416B2 (en) | Electrically induced vessel vasodilation | |
| US6233482B1 (en) | Method of electroporation mediated delivery of drugs and genes | |
| DE69528604T2 (de) | Medikamentenbehandlung erkrankter tiefliegender bereiche im inneren des körpers | |
| US6216034B1 (en) | Method of programming an array of needle electrodes for electroporation therapy of tissue | |
| DE69604509T2 (de) | Vorrichtung zur verabreichung von medikamenten und genen durch elektroporation | |
| DE69927216T2 (de) | Vorrichtung zur elektroporation mit einer sich anschliessenden elektrodenschablone | |
| US7412284B2 (en) | Apparatus for electroporation mediated delivery for drugs and genes | |
| DE60030334T2 (de) | Vorrichtung zur myokardwiederherstellung bei myokard-infarkt | |
| US20040219660A1 (en) | Electroporation-mediated intravascular delivery | |
| DE69915235T2 (de) | Implantierbares system, das medikamente freisetzende zellen enthält, für eine bedarfsgerechte, lokale verabreichung von medikamenten | |
| US20040204669A1 (en) | Apparatus for electroporation mediated delivery for drugs and genes | |
| DE69936866T2 (de) | Synergismus von photodynamischen und elektropermeationseffekten auf die zellvitalität als ein neues cytotoxisches mittel | |
| DE19529909C2 (de) | Wässrige Spüllösung | |
| DE4019208A1 (de) | Nervenregenerationsmittel | |
| Engelmann et al. | Einfluss von Cisplatin auf die Heilung von Darmanastomosen der Ratte: Mikroangiographische und lichtmikroskopische Untersuchungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |